Mannkind (MNKD) Non-Current Deffered Revenue (2017 - 2026)
Mannkind's (MNKD) quarterly Non-Current Deffered Revenue came in at $38.9 million in Q1 2026, down 17.85% year-on-year from $47.4 million in Q1 2025, and down 2.68% on a QoQ basis from $40.0 million in Q4 2025.
Mannkind (MNKD) Non-Current Deffered Revenue (2017 - 2026) Analysis & Trends
Mannkind (MNKD) has 10 years of Non-Current Deffered Revenue data on file, last reported at $38.9 million in Q1 2026.
- On a quarterly basis, Non-Current Deffered Revenue fell 17.85% year-over-year to $38.9 million in Q1 2026; TTM through Mar 2026 was $38.9 million, a 17.85% decrease from a year earlier, with the FY2025 full-year figure at $40.0 million, down 21.86% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $38.9 million, down from $40.0 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for MNKD reached as high as $69.8 million in Q4 2023 and fell as low as $1.2 million in Q1 2023.
- Historically, Non-Current Deffered Revenue has averaged $46.8 million across 5 years, with a median of $47.4 million in 2025.
- Across the five-year window, Non-Current Deffered Revenue slumped 95.41% in 2023 and surged 5545.08% in 2024, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $37.7 million in 2022, then jumped by 85.21% to $69.8 million in 2023, then retreated by 26.7% to $51.2 million in 2024, then slipped by 21.86% to $40.0 million in 2025, then retreated by 2.68% to $38.9 million in 2026.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $38.9 million in Q1 2026, $40.0 million in Q4 2025, and $48.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Mannkind | 1.20 Bn | 1.07 Bn | 82.66 Mn | 38.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.91 Mn |
| Dec 31, 2025 | 39.98 Mn |
| Sep 30, 2025 | 48.19 Mn |
| Jun 30, 2025 | 45.47 Mn |
| Mar 31, 2025 | 47.36 Mn |
| Dec 31, 2024 | 51.16 Mn |
| Sep 30, 2024 | 65.15 Mn |
| Jun 30, 2024 | 66.12 Mn |
| Mar 31, 2024 | 67.74 Mn |
| Dec 31, 2023 | 69.79 Mn |
| Sep 30, 2023 | 69.47 Mn |
| Jun 30, 2023 | 60.25 Mn |
| Mar 31, 2023 | 1.20 Mn |
| Dec 31, 2022 | 37.68 Mn |
| Sep 30, 2022 | 32.00 Mn |
| Jun 30, 2022 | 29.76 Mn |
| Mar 31, 2022 | 26.12 Mn |
| Dec 31, 2021 | 19.54 Mn |
| Sep 30, 2021 | 1.55 Mn |
| Jun 30, 2021 | 1.59 Mn |